Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) glycolic ester of diclofenac, used for certain joint disorders. It has a better tolerability profile as well as a better analgesic activity in comparison with diclofenac. Hence, developing formulation strategies for aceclofenac is particularly imperative1,2.
Currently, the marketed formulation contains a tablet and a gel. However, side effects such as gastric ulcerogenicity, flatulence, indigestion and nausea, limit the utility of oral aceclofenac1. Hence, the topical route would be one of the ideal alternatives to enhance local delivery, bypassing these side effects. Compared with ointments and creams, gelsprovide a better feel are greaseless and easily washable. Additionally, a gel formulation aids in faster drug release in comparison to other semisolids2.
However, a prominent drawback in formulating gels is difficulty in delivery of hydrophobic drug. To overcome this limitation, emulgel, a novel drug delivery has emerged which is a combination of gel and emulsion, where the presence of gelling agent in the water phase converts a classical emulsion into a gel. It combines dual release pattern of both gel and emulsion providing better therapeutic action and sustained release3,4.
Microemulsion-based formulations have an advantage of improved solubility and have reported to enhance drug permeation, owing to reduced surface tension and particle size5,6. Microemulsions are thermodynamically stable and enhance drug permeation and release. Hence, a microemulsion of Aceclofenac was formulated, which was later formed into an emulgel.
Data regarding formulation of microemulsion-based emulgel of aceclofenac are limited and none of the previously published studies present a comparison of the aceclofenac emulgel with the currently marketed, most popular anti-inflammatory emulgel, diclofenac. Thus, the study was conducted to develop novel microemulsion-based emulgel formulations of aceclofenac, a poorly water soluble drug and evaluate its anti-inflammatory activity. The current study focused on the development and optimization of an emulgel formulation of aceclofenac and evaluation of its anti-inflammatory activity against the standard, most preferred marketed Diclofenac emulgel in experimental animals.
MATERIALS AND METHODS
The study was conducted in the research lab of department of pharmacology, NMIMS University. The study was commenced after the relevant approvals from the concerned authorities as well as the animal ethics committee. The animal studies were conducted in the animal house, under appropriate care and precautions. The total duration of this study was approximately 5 months considering conceptualization to completion of animal studies. The study was initiated in December, 2015 and completed in May, 2016.
FORMULATION6-8: Preparation of microemulsion: Aceclofenac was obtained as a gift sample from FDC Limited (Mumbai, India). Polysorbate 80, isopropyl myristate, was procured from Molychem (Mumbai, India) and Loba chemie pvt limited, (Mumbai, India), respectively. All other chemicals and solvents were of analytical reagent grade.
Saturation solubility of aceclofenac in various oils, surfactants, co-surfactants was determined by saturation solubility method. Based on the results of this study, pseudo ternary phase diagram was plotted using the Tridraw software, to calculate the surfactant and co-surfactant ratio (Smix). After a number of trials, microemulsion of aceclofenac was optimized with:
||5.74% of Isopropyl myristate
||51.72% of polysorbate 80: ethanol mixture (Smix) in 1:1 ratio
||42.52% of aqueous phase
Oil was mixed in the Smix for around 10 min on a magnetic stirrer. Aceclofenac was added to it in small parts until the drug completely dissolved in the solution. The optimized quantity of distilled water was then added drop by drop in the solution with constant stirring at 50rpm on a magnetic stirrer.
Emulgel was prepared by using carbopol 940 which was soaked overnight, adjusted pH with triethanolamine followed by addition of microemulsion equivalent to 1% of aceclofenac. Different concentrations of carbopol 940 were taken for trials and the optimum emulgel formulation was selected (Table 1 and Fig. 1).
Evaluation of microemulsion4-7
Appearance and pH: The test substance was inspected visually for color, consistency and pH (LabIndia, PICO+, Mumbai, India).
Dilution capacity: The test substance was diluted in 1:10 and 1:100 ratios with double distilled water and observed visually for cracking of the system.
|Fig. 1:||Pseudo ternary phase diagram at 1:1 and 1:2 surfactants to co-surfactant ratio
|Table 1:||Formulation trials for emulgel
Particles size and zeta potential: The particle size and zeta potential of the microemulsion was evaluated using nano zeta sizer.
Specifications of the zeta sizer:
||Model:ZS 90, Particle size range: 3 nm to 10 μm
In vitro diffusion studies: In vitro diffusion studies were done with the help of modified Franz diffusion cell (Sumati sales corporation, Mumbai, India). Microemulsion containing 15 mg of aceclofenac was evenly applied onto the surface of dialysis membrane along with aceclofenac suspension in water for comparison. The dialysis membrane was attached between the donor and the receptor chamber of diffusion cell. The receptor chamber was filled with freshly prepared phosphate buffer (pH 6.8). The receptor chamber was stirred by magnetic stirrer. The aliquots (1 mL) were collected at time intervals of 1 h up to 8 h. Samples were analyzed for drug content by UV-Vis spectrophotometer after appropriate dilutions. Cumulative corrections were made to obtain the total amount of drug release at each time interval.
Evaluation of emulgel7-11
Optimization: F1 and F2 with 0.66 and 1.5% concentration of carbopol 944, respectively, on addition of microemulsion, formed a gel with low viscosity. Hence, F3 with 1.88% of carbopol 940 was finalized for formulation of emulgel.
Appearance and pH: The test substance was inspected visually for color, consistency and pH (LabIndia, PICO+, Mumbai, India).
In vitro diffusion studies: These studies were conducted in the same way as that described for microemulsion, but by using the emulgel in the place of microemulsion.
Ex-vivo diffusion studies: Ex-vivo studies were done in the same manner as that of in vitro diffusion studies where the dialysis membrane was replaced with rat skin. The average cumulative amount of drug permeated per unit surface area of the skin was plotted versus time.
Drug content determination: Aceclofenac content in emulgel was measured by dissolving known 0.5 g of emulgel in methanol by sonication. Absorbance was measured after suitable dilution at 277 nm using UV-Vis spectrophotometer.
Animal studies: The protocol designed for animal studies was compliant with the CPCSEA guidelines and was approved by the institutional animal ethics committee. Ethics committee approval number: 1830/PO/Re/S/15/CPCSEA.
Skin irritation test (patch test)7-10: A set of nine rats was used in the study. The emulgel was applied on the properly shaven skin of rat. Undesirable skin changes, i.e., change in color, change in skin morphology were checked for a period of 24 h.
Anti-inflammatory studies by carrageenan induced paw edema model: A total of 6 rats were used in each group, for placebo, marketed gel and aceclofenac formulated emulgel, amounting to 18 rats in total.
The anti-inflammatory activity of aceclofenac emulgel was evaluated using carrageenan induced paw edema in rats by a method described by Gerald et al. Female wistar rats weighing 150-200 g were divided into three groups. Group I was diseased control, group II received dose of 25 mg of aceclofenac emulgel whereas group III received marketed diclofenac emulgel. Edema was induced in rats using 0.1 mL of 1% carrageenan solution in 0.9% saline solution into the sub plantar region of right hind paw of the rat. The swelling in the paw of each rat was measured by plethysmometer by volume displacement method at baseline and every h till the 6th h11. Percentage inflammation was calculated as under:
||Paw thickness at each time interval
||Initial paw thickness
The average paw swelling in the drug treated rats was compared with that of control rats and the% inhibition of edema was calculated as:
||Edema rate of control group
||Edema rate of the treated group
Anti-inflammatory studies by croton oil induced ear edema: The anti-inflammatory activity of aceclofenac emulgel was evaluated using croton oil induced ear edema against acute inflammation. Ear edema was induced by topical application of 8% croton oil in mixture of solvents (percentage, croton oil: Ethanol: Pyridine: Diethyl ether = 8: 10: 20: 62) on the outer and inner surfaces of the right ear of each rat. Wistar rats (150-200 g) were divided randomly into three groups. Group I was taken as disease control. Group II received aceclofenac emulgel equivalent to 2.5 mg of drug whereas group III received marketed voltaren emulgel equivalent to 2.5 mg of drug. The inflammation in the ear of each rat was noted using Vernier caliper at 1st, 2nd, 3rd and 4th h of treatment. The percentage change in inflammation was calculated by the same formula as mentioned above.
Statistical analysis: Experimental values were expressed as Mean±SD. The data were analyzed by one way analysis of variance (ANOVA) followed by Bonferronis multiple comparison test. A value of p<0.05 was considered as significant.
Optimization of microemulsion: The solubility of aceclofenac in different oils, surfactants and co-surfactants was determined since it is the most important criteria for microemulsion preparation (Table 2).
The solubilization capability of aceclofenac in different oils, surfactant and co surfactant was shown in the Table 1. Isopropyl myristate showed best solubility amongst all the oils, polysorbate 80 showed two times better solubility than other surfactants and Ethanol showed the 5 times better solubility amongst co-surfactants. Based on the results of solubility studies, Isopropyl myristate, Polysorbate 80 and Ethanol were chosen as oil, surfactant and co-surfactant, respectively.
|Table 2:||Solubility of aceclofenac in various oils, surfactants and co-surfactants
||Particle size analysis report by nano zetasizer
Pseudo ternary phase diagram was constructed by varying Polysorbate 80 and ethanol in 1:1 and 1:2 ratios (Fig. 1).
The microemulsion region obtained in 1:1 ratio was more as compared with that of 1:2 ratio of Smix. The particle size of 1:1 ratio of Smix was found to be 31.36 nm whereas that for 1:2 ratios was found to be 57.57 nm. Hence, 1:1 ratio of Smix (Polysorbate 80: Ethanol) was chosen for further studies. The microemulsion which had highest amount of drug solubility and water uptake in the pseudo ternary phase diagram was chosen for trials on microemulsion. A formulation yielding clear and transparent appearance and the one not cracking when observed for 24 h was selected for further studies.
Evaluation of microemulsion
Appearance and Ph: The aceclofenac microemulsion was transparent yellow colored solution with a pH of 5.52.
Dilution capacity: The microemulsion when diluted in 1:10 and 1:100 ratios with double distilled water, clear solution was obtained which had a slight bluish tinge, no breaking of the system was observed.
Particle size and Zeta potential analysis: The particle size of the microemulsion was found to be 31.36 nm (Fig. 2) and zeta potential of the microemulsion was found to be 0.00835 (Fig. 3).
In vitro diffusion studies: The drug release was found to be 94.46 and 47.38% of aceclofenac microemulsion and plain dispersion aceclofenac, respectively in 6 h (Fig. 4).
Formulation, development and evaluation of emulgel: Emulgel was prepared by using carbopol 940 which was soaked overnight, adjusted pH with triethanolamine followed by addition of microemulsion equivalent to 1% of aceclofenac. Different concentrations of carbopol 940 were taken for trials and the optimum emulgel formulation (F3) was selected, (Table 1 and Fig. 1). F1 and F2 with 0.66 and 1.5% concentration of carbopol 944, respectively, on addition of microemulsion, formed a gel with low viscosity. Hence, F3 with1.88% of carbopol 940 was finalized for formulation of emulgel.
Appearance and pH: The aceclofenac emulgel obtained was a white translucent gel with a pH of 6.72.
In vitro diffusion studies: The in vitro drug release of emulgel was found to be 83.54% in 8 h (Fig. 5).
Ex-vivo diffusion studies: Ex-vivo drug release of emulgel was found to be 71.88% in 8 h (Fig. 6).
In vivo studies
Skin irritation test: No allergic symptoms like inflammation, redness, irritation appeared on rats up to 24 h.
Carrageenan induced paw edema model: In case of control, inflammation showed an increase till 4 h, followed by a slight reduction. Animals treated with aceclofenac emulgel showed a significant reduction in the paw volume (p<0.05) compared to control by 64%, at the end of 6 h. Inflammation increased for the first 2 h, followed by gradual reduction, an observation starkly distinct from the control.
|Fig. 3:||Zeta potential analysis report by nano zetasizer
|Fig. 4:||Plot of comparative cumulative drug release
|Fig. 5:||In vitro diffusion studies
Voltaren emulgel produced maximum inhibition of 77.74% by the end of 6 h (Table 3).
Croton oil induced ear edema: The trend in inflammation and reduction was similar as observed with the first model, in the respective groups.
|Fig. 6:||Ex vivo diffusion studies
|Table 3:||Results of carrageenan induced Paw Edema model
|Table 4:||Results of croton oil induced Ear Edema model
Aceclofenac emulgel demonstrated significant (p<0.05, nearly half) reduction in inflammation by end of the 4th h compared to the control (Table 4) Voltaren emulgel presented maximum inhibition of 55.8% in 4 h.
The anti-inflammatory activity was numerically more in voltaren emulgel as compared to aceclofenac emulgel. However, these differences were not statistically significant.
In this investigation, a microemulsion-based emulgel of aceclofenac was successfully formulated, which lead to improved solubility and drug release of aceclofenac. Moreover, the improvement in solubility and drug release translated into an effective biological activity, when tested in animal models of inflammation, the formulated microemulsion-based emulgel brought about an effective anti-inflammatory activity, reducing the inflammation by more than 50% compared to placebo alone, 55.8 and 64% in paw edema and ear edema animal models, respectively. Most remarkable finding was that the anti-inflammatory activity exhibited by aceclofenac microemulsion-based emulgel.
The dual novel technique viz. microemulsion formulation, further incorporation into a gel and its influence on the anti-inflammatory activity is not reported elsewhere in the previous literature. Microemulsion formulation aids in improving the drug solubility owing to reduced particle size, improved surface tension and better permeation. Additionally, microemulsions have improved stability12-14.
Previous studies have attempted formulation of aceclofenac in emulgels and gels, however, the data regarding formulation of microemulsion-based emulgel of aceclofenac and head-to-head comparison of anti-inflammatory activity with the most popular marketed emulgel is not reported in the literature15-18.
In an earlier study conducted by Pani et al.15, aceclofenac was attempted in an emulgel formulation, using mentha oil as a penetration enhancer. The study revealed that the formulation with carbopol 934 shown better release profile than HPMC K4M, depicting carbopol 934 as the better choice of polymer for aceclofenac emulgel. In another study by Shah et al.16, a microemulsion base for aceclofenac was formulated using isopropyl myristate 5%, labrasol/plurol oleique 45% (4:1) and water, which yielded an ex vivo release of 95%.
Additionally, a study conducted by Patel et al.17 analyzed the effect of various gelling agents on the release profile of aceclofenac, among all the gel formulations, carbopol exhibited superior drug release than followed by Na CMC, HPMC and sodium alginate. Similar investigation by Pottalaswathi and Vema18, reiterated these findings that incorporation of Carbopol in an emulgel of aceclofenac improves its penetration18. Herein, no further evaluation and animal studies were done to assess the implications of the formulation in vivo. Hence, we addressed the issues of previously published studies, presenting a novel research. In view of the foregoing, we attempted to formulate a microemulsion based emulgel of aceclofenac and tested the efficacy of the formulation in animal models of inflammation. Moreover, we compared our formulation with the most commonly preferred anti-inflammatory emulgel brand, VOLTAREN.
The micro emulsion formulation developed in this maneuver was found to be satisfactory in terms of physical characteristics like clarity, particle size as well and in vitro drug diffusion (Fig. 1-4) compared with the simple aqueous dispersion of the drug. This is indicative of the improved solubility brought about by the microemulsion formulation. Testing for the drug release from the micro emulsion itself is critical prior to designing an emulgel. Hence, the micro emulsion was considered optimum in terms of these pharmaceutical characteristics.
The objective to formulate an emulgel using non-irritating and pharmaceutically acceptable ingredients was achieved. The emulgel was studied in terms of physical characteristics, particle size, skin irritation test and drug release and was found satisfactory, achieving more than 75% drug release at the end of 8 h. Thus, the formulated emulgel was considered optimum, based on the pharmaceutical characteristics and further subjected to animal testing for anti-inflammatory activity using two animal models viz. Carrageenan induced paw edema and croton ear edema model.
Carrageenan induced paw edema and croton induced ear edema model have been frequently used to assess the edematous effect of the contribution of mediators involved in vascular changes associated with acute inflammation. Both of these models differ in terms of underlying pathways of the inflammatory cascade. An effective anti-inflammatory drug is purported to act via both the pathways, thus mitigating inflammation. In this regard, the activity of aceclofenac in alleviating inflammation was evaluated as measure of the efficiency of the formulation and thereby, the drug release. In both the models, animals treated with aceclofenac emulgel showed inflammation reversal in 2 h of application, resulting in improved inhibition of inflammation with an effect lasting up to 6 h. These results were concordant with the study conducted by Fathalla et al.5. A similar effect was observed with the marketed diclofenac formulation, which reinforces the proof of efficiency of the marketed gel in delivering diclofenac and reducing inflammation. On the contrary, in the placebo group inflammation persisted till the 4th h and later showed a decline which was statistically insignificant compared to the treated groups, which reinstates the efficacy of aceclofenac, lack of any activity attributed to excipients and effective delivery of the drug. In both the models, the inflammatory edema reached its maximum level at the 4h and later started declining. The late phase of the inflammatory response has been shown to be due to potentiating effect of bradykinin on mediator release and prostaglandins, producing edema after mobilization of the leukocytes as studied by Necas and Bartosikova19 and Siqueira et al.20. Hence, the study yields valuable insights into improving the solubility of a BCS class II drug, through a microemulsion based emulgel. Moreover, the effectiveness of the formulation in delivering the drug as manifested in vitro and ex vivo studies, was transposed into significantly mitigating inflammation in animal models. Although, the pharmacological evidence presented herein, shows a quantitatively higher activity for the marketed preparation, the designed formulation was at par with the marketed one with significantly better activity demonstrated against the placebo. Aceclofenac exhibits a better tolerability profile compared to diclofenac when taken orally. However, the implications of this phenomenon, when the drugs are administered topically remain a question to be addressed in future studies. Secondly, relevance of this fact is even more when the respective drugs are taken life-long in chronic conditions like arthritis. In this regard, the study provides a preliminary comparative efficacy data for both the drugs, providing a foundation for a robust clinical evaluation in future studies.
Thus, the microemulsion based aceclofenac emulgel showed promising results as an effective anti-inflammatory topical drug delivery system, in this preliminary investigation. Moreover, the reduction in inflammation was comparable to that of the most consumer preferred anti-inflammatory emulgel brand of diclofenac. Thus, manifesting a comparable activity and a better tolerability profile of aceclofenac to that of diclofenac, the former may provide an edge over the latter, for topical activity. However, further research is warranted focusing on formulation stability and more in vivo studies to substantiate the potential of the emulgel formulation as robust and efficacious topical based drug delivery system of aceclofenac.
The study yields novel insights into the formulation strategies for designing a water soluble novel drug delivery system of an anti-inflammatory, low-solubility drug aceclofenac. The study also highlights preclinical analysis, that aceclofenac and diclofenac show equal efficacy when used topically. The findings of the study may yield further avenues for researchers as well as formulation scientists to design further studies on aceclofenac emulgel formulations, using the optimized microemulsion techniques.
We acknowledge SPPSPTM, SVKMs NMIMS, Mumbai for providing funding and facilities to execute the study.